152 related articles for article (PubMed ID: 31209687)
61. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
62. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
[TBL] [Abstract][Full Text] [Related]
63. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Liu S; Tang Y; Yan M; Jiang W
Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
[TBL] [Abstract][Full Text] [Related]
64. Phosphoinositide 3-kinase signaling in retinal rod photoreceptors.
Ivanovic I; Allen DT; Dighe R; Le YZ; Anderson RE; Rajala RV
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):6355-62. PubMed ID: 21730346
[TBL] [Abstract][Full Text] [Related]
65. High incidence of PI3K pathway gene mutations in South Indian cervical cancers.
Rose MM; Dhamodharan S; Revathidevi S; Chakkarappan SR; Jagadeesan MG; Subbiah S; Nakaoka H; Inoue I; Murugan AK; Munirajan AK
Cancer Genet; 2022 Jun; 264-265():100-108. PubMed ID: 35568000
[TBL] [Abstract][Full Text] [Related]
66.
D'Ambrosio C; Erriquez J; Arigoni M; Capellero S; Mittica G; Ghisoni E; Borella F; Katsaros D; Privitera S; Ribotta M; Maldi E; Di Nardo G; Berrino E; Venesio T; Ponzone R; Vaira M; Hall D; Jimenez-Linan M; Paterson AL; Calogero RA; Brenton JD; Valabrega G; Di Renzo MF; Olivero M
Cells; 2020 Feb; 9(2):. PubMed ID: 32075097
[TBL] [Abstract][Full Text] [Related]
67. Somatic mutations of PIK3R1 promote gliomagenesis.
Quayle SN; Lee JY; Cheung LW; Ding L; Wiedemeyer R; Dewan RW; Huang-Hobbs E; Zhuang L; Wilson RK; Ligon KL; Mills GB; Cantley LC; Chin L
PLoS One; 2012; 7(11):e49466. PubMed ID: 23166678
[TBL] [Abstract][Full Text] [Related]
68. The Role of PIK3R1 in Metabolic Function and Insulin Sensitivity.
Tsay A; Wang JC
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628845
[TBL] [Abstract][Full Text] [Related]
69. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Weber GL; Parat MO; Binder ZA; Gallia GL; Riggins GJ
Oncotarget; 2011 Nov; 2(11):833-49. PubMed ID: 22064833
[TBL] [Abstract][Full Text] [Related]
70. p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
Mak VC; Li X; Rao L; Zhou Y; Tsao SW; Cheung LW
Neoplasia; 2021 Jul; 23(7):718-730. PubMed ID: 34144267
[TBL] [Abstract][Full Text] [Related]
71. A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism.
Thapa N; Chen M; Cryns VL; Anderson R
Cell Rep; 2024 May; 43(5):114119. PubMed ID: 38630589
[TBL] [Abstract][Full Text] [Related]
72. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
73. Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Li X; Lau AYT; Ng ASN; Aldehaiman A; Zhou Y; Ng PKS; Arold ST; Cheung LWT
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507989
[TBL] [Abstract][Full Text] [Related]
74. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.
Muellner MK; Uras IZ; Gapp BV; Kerzendorfer C; Smida M; Lechtermann H; Craig-Mueller N; Colinge J; Duernberger G; Nijman SM
Nat Chem Biol; 2011 Sep; 7(11):787-93. PubMed ID: 21946274
[TBL] [Abstract][Full Text] [Related]
75. Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation.
Yamaguchi H; Yoshida S; Muroi E; Yoshida N; Kawamura M; Kouchi Z; Nakamura Y; Sakai R; Fukami K
J Cell Biol; 2011 Jun; 193(7):1275-88. PubMed ID: 21708979
[TBL] [Abstract][Full Text] [Related]
76. Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth.
Cottrell CE; Bender NR; Zimmermann MT; Heusel JW; Corliss M; Evenson MJ; Magrini V; Corsmeier DJ; Avenarius M; Dudley JN; Johnston JJ; Lindhurst MJ; Vigh-Conrad K; Davies OMT; Coughlin CC; Frieden IJ; Tollefson M; Zaenglein AL; Ciliberto H; Tosi LL; Semple RK; Biesecker LG; Drolet BA
Genet Med; 2021 Oct; 23(10):1882-1888. PubMed ID: 34040190
[TBL] [Abstract][Full Text] [Related]
77. A novel mutant PIK3R1
Wang K; Hu Y; Xu L; Zhao S; Song C; Sun S; Li X; Li M
Mol Biol Rep; 2022 Jul; 49(7):6155-6160. PubMed ID: 35384625
[TBL] [Abstract][Full Text] [Related]
78. Divergent roles of the regulatory subunits of class IA PI3K.
Kim CW; Lee JM; Park SW
Front Endocrinol (Lausanne); 2023; 14():1152579. PubMed ID: 38317714
[TBL] [Abstract][Full Text] [Related]
79. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
Chudasama KK; Winnay J; Johansson S; Claudi T; König R; Haldorsen I; Johansson B; Woo JR; Aarskog D; Sagen JV; Kahn CR; Molven A; Njølstad PR
Am J Hum Genet; 2013 Jul; 93(1):150-7. PubMed ID: 23810379
[TBL] [Abstract][Full Text] [Related]
80. Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors.
Liu Y; Wang D; Li Z; Li X; Jin M; Jia N; Cui X; Hu G; Tang T; Yu Q
Sci Rep; 2022 Apr; 12(1):5924. PubMed ID: 35395865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
